Herein, firstly, we report two cases of resectable ALK-positive lung adenocarcinoma receiving more than six months of alectinib as neoadjuvant therapy followed by radical surgical resection to achieve pathological complete responses. Here, ALK is linked to lung adenocarcinoma.